LFWD icon

ReWalk Robotics

0.5487 USD
-0.0108
1.93%
At close Updated Sep 17, 4:00 PM EDT
Pre-market
After hours
0.5401
-0.0086
1.57%
1 day
-1.93%
5 days
-2.05%
1 month
-14.1%
3 months
-50.12%
6 months
-65.49%
Year to date
-75.39%
1 year
-82.64%
5 years
-93.3%
10 years
-99.97%
 

About: Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings are the ReWalk Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES bikes, and AlterG Anti-Gravity systems. It operates through markets in the United States, Israel, and Germany.

Employees: 80

0
Funds holding %
of 7,463 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

432% more call options, than puts

Call options by funds: $250K | Put options by funds: $47K

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

6% more funds holding

Funds holding: 16 [Q1] → 17 (+1) [Q2]

0.55% more ownership

Funds ownership: 1.76% [Q1] → 2.31% (+0.55%) [Q2]

26% less capital invested

Capital invested by funds: $319K [Q1] → $237K (-$82.3K) [Q2]

Financial journalist opinion

Based on 3 articles about LFWD published over the past 30 days

Positive
Zacks Investment Research
8 days ago
Lifeward Achieves European Approval for Latest ReWalk Exoskeleton
LFWD secures CE mark for its ReWalk 7 Personal Exoskeleton, unlocking new European sales potential with advanced features.
Lifeward Achieves European Approval for Latest ReWalk Exoskeleton
Neutral
GlobeNewsWire
8 days ago
First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton
Medicare Advantage claim processed in less than thirty days Additional progress with traditional Medicare claim approvals has accelerated timelines to payment in 2025 MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept.
First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton
Neutral
GlobeNewsWire
9 days ago
Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton
Seventh generation of industry-leading ReWalk Exoskeleton is now cleared for commercial launch in the European Union Seventh generation of industry-leading ReWalk Exoskeleton is now cleared for commercial launch in the European Union
Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton
Neutral
Seeking Alpha
1 month ago
Lifeward Ltd. (LFWD) Q2 2025 Earnings Call Transcript
Lifeward Ltd. (NASDAQ:LFWD ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Almog Adar - Chief Financial Officer William Mark Grant - President, CEO & Director Conference Call Participants Benjamin Charles Haynor - Lake Street Capital Markets, LLC, Research Division I-Eh Jen - Laidlaw & Company (UK) Ltd.
Lifeward Ltd. (LFWD) Q2 2025 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Lifeward (LFWD) Reports Q2 Loss, Lags Revenue Estimates
Lifeward (LFWD) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.5 per share a year ago.
Lifeward (LFWD) Reports Q2 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Lifeward Ltd. Reports Second Quarter 2025 Financial Results
Achieves r ecord n umber of ReWalk s ystems p laced f or Medicare b eneficiaries s ince fee schedule established Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process A ppoints n ew CEO and CFO to s pearhead s trategic c hange and a ccelerate g rowth MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) --  Lifeward Ltd.
Lifeward Ltd. Reports Second Quarter 2025 Financial Results
Neutral
GlobeNewsWire
1 month ago
Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Almog Adar, who previously served as the Company's Vice President of Finance and Chief Accounting Officer, has been appointed as the Company's new Chief Financial Officer.
Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership
Neutral
GlobeNewsWire
1 month ago
Lifeward to Report Second Quarter Financial Results on August 14, 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its second quarter 2025 financial results before the markets open on Thursday, August 14, 2025.
Lifeward to Report Second Quarter Financial Results on August 14, 2025
Neutral
GlobeNewsWire
1 month ago
Lifeward Expands Distribution Partnership with SportsMed Ltd. to Add Coverage for United Arab Emirates and Entire Gulf Cooperation Council Region
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Lifeward Expands Distribution Partnership with SportsMed Ltd. to Add Coverage for United Arab Emirates and Entire Gulf Cooperation Council Region
Neutral
PRNewsWire
2 months ago
MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion
Industry veteran with proven track record in neurorehabilitation and fundraising to lead next phase of growth; Co-founder Brian Harris transitions to Chief Scientific Officer PORTLAND, Maine , July 7, 2025 /PRNewswire/ -- MedRhythms, Inc., a company pioneering the development of next-generation neurotherapeutics to improve walking, mobility and related functional outcomes, and creator of the world's first prescription music platform, announced the appointment of Larry Jasinski as Chief Executive Officer, effective immediately. Co-founder of MedRhythms, Brian Harris, who led the company through product development, successful clinical trials, listing product with the Food and Drug Administration (FDA), and assignment by the Centers for Medicare and Medicaid Services (CMS) of a benefit category and unique Health Care Common Procedure Coding System (HCPCPS) code, will transition to the role of Chief Scientific Officer (CSO) and work with Larry to build the market and grow the company in its next phase.
MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion
Charts implemented using Lightweight Charts™